Galena Biopharma Inc (NASDAQ:GALE) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.01, Morningstar.com reports. During the same period in the previous year, the business earned $0.05 earnings per share.

Galena Biopharma (NASDAQ GALE) traded down 3.4146% on Tuesday, reaching $0.3564. The company’s stock had a trading volume of 364,843 shares. The firm’s market capitalization is $13.34 million. Galena Biopharma has a 52-week low of $0.26 and a 52-week high of $9.10. The firm has a 50-day moving average price of $0.54 and a 200 day moving average price of $0.64.

Several brokerages recently weighed in on GALE. Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a report on Wednesday, August 9th. Zacks Investment Research downgraded Galena Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, ValuEngine downgraded Galena Biopharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GALE. Renaissance Technologies LLC bought a new position in Galena Biopharma during the first quarter worth about $976,000. Vanguard Group Inc. raised its position in Galena Biopharma by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock worth $774,000 after buying an additional 13,302 shares in the last quarter. Finally, Virtu KCG Holdings LLC raised its position in shares of Galena Biopharma by 677.4% in the second quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock worth $130,000 after buying an additional 195,230 shares during the period. Institutional investors and hedge funds own 21.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Galena Biopharma Inc (GALE) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/galena-biopharma-inc-gale-releases-quarterly-earnings-results-misses-expectations-by-0-01-eps/1491580.html.

About Galena Biopharma

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Earnings History for Galena Biopharma (NASDAQ:GALE)

Receive News & Ratings for Galena Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.